| Post-acute COVID-19 syndrome A Nalbandian, K Sehgal, A Gupta, MV Madhavan, C McGroder, ... Nature medicine 27 (4), 601-615, 2021 | 4581 | 2021 |
| Extrapulmonary manifestations of COVID-19 A Gupta, MV Madhavan, K Sehgal, N Nair, S Mahajan, TS Sehrawat, ... Nature medicine 26 (7), 1017-1032, 2020 | 3464 | 2020 |
| Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research B Bikdeli, MV Madhavan, A Gupta, D Jimenez, JR Burton, ... Thrombosis and haemostasis 120 (07), 1004-1024, 2020 | 294 | 2020 |
| Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets K Sehgal, R Das, L Zhang, R Verma, Y Deng, M Kocoglu, J Vasquez, ... Blood, The Journal of the American Society of Hematology 125 (26), 4042-4051, 2015 | 133 | 2015 |
| Targeting human dendritic cells in situ to improve vaccines K Sehgal, KM Dhodapkar, MV Dhodapkar Immunology letters 162 (1), 59-67, 2014 | 109 | 2014 |
| Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy K Sehgal, RR Gill, P Widick, P Bindal, DC McDonald, M Shea, ... JAMA network open 4 (2), e2037120-e2037120, 2021 | 98 | 2021 |
| Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer L Ostios-Garcia, J Faig, GC Leonardi, AE Adeni, SJ Subegdjo, CA Lydon, ... Journal of Thoracic Oncology 13 (7), 1037-1042, 2018 | 92 | 2018 |
| Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors K Sehgal, R Patell, D Rangachari, DB Costa Translational cancer research 7 (Suppl 7), S779, 2018 | 57 | 2018 |
| Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk K Sehgal, R Ragheb, TM Fahmy, MV Dhodapkar, KM Dhodapkar The Journal of Immunology 193 (5), 2297-2305, 2014 | 51 | 2014 |
| Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade K Sehgal, A Portell, EV Ivanova, PH Lizotte, NR Mahadevan, JR Greene, ... The Journal of clinical investigation 131 (2), 2021 | 42 | 2021 |
| Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? K Sehgal, A Varkaris, H Viray, PA VanderLaan, D Rangachari, DB Costa Journal for Immunotherapy of Cancer 8 (1), 2020 | 40 | 2020 |
| Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia K Sehgal, X Guo, S Koduru, A Shah, A Lin, X Yan, KM Dhodapkar Science translational medicine 5 (193), 193ra89-193ra89, 2013 | 33 | 2013 |
| Association of pretreatment circulating tumor tissue–modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer EM Rettig, AA Wang, NA Tran, E Carey, T Dey, JD Schoenfeld, K Sehgal, ... JAMA Otolaryngology–Head & Neck Surgery 148 (12), 1120-1130, 2022 | 28 | 2022 |
| Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? K Sehgal, AJ Piper-Vallillo, H Viray, AM Khan, D Rangachari, DB Costa Precision cancer medicine 3, 2020 | 27 | 2020 |
| Association between immune-related adverse events and clinical outcomes to programmed cell death protein 1/programmed death-ligand 1 blockade in SCLC B Ricciuti, AR Naqash, J Naidoo, K Sehgal, A Miller, K Kehl, ... JTO Clinical and Research Reports 1 (4), 100074, 2020 | 23* | 2020 |
| Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations K Sehgal, D Rangachari, PA VanderLaan, SS Kobayashi, DB Costa The oncologist, 2020 | 20 | 2020 |
| Hyperprogression in patients with cancer receiving immune checkpoint inhibitors K Sehgal JAMA Network Open 4 (3), e211839-e211839, 2021 | 18 | 2021 |
| Extended-interval dosing strategy of immune checkpoint inhibitors in lung cancer: will it outlast the COVID-19 pandemic? K Sehgal, DB Costa, D Rangachari Frontiers in Oncology 10, 1193, 2020 | 17 | 2020 |
| Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer K Sehgal, A Bulumulle, H Brody, RR Gill, S Macherla, A Qilleri, ... Clinical lung cancer 22 (3), e379-e389, 2021 | 14 | 2021 |
| Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes A Bikas, S Ahmadi, T Pappa, E Marqusee, K Wong, MA Nehs, NL Cho, ... Clinical Cancer Research 29 (14), 2678-2685, 2023 | 8 | 2023 |
